About Passage Bio
Passage Bio is a publicly listed company based in Philadelphia (United States) founded in 2017 by Stephen Squinto. Gene therapies for CNS rare diseases are developed. Passage Bio has raised $225.5 million across 3 funding rounds from investors including New Leaf Venture Partners, Orbimed and Frazier Healthcare Partners. The company has 60 employees. Its chief executive, as recorded, is William Chou. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its competitors include BridgeBio, Spark Therapeutics and Alnylam; 3 of its 3 listed competitors have raised funding.
Company details
Passage Bio was founded in 2017 in Philadelphia, United States, within the biotechnology sector. AAV-delivered therapeutics are developed for rare monogenic central nervous system diseases. Lead programs are directed toward GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease. Operations center on advancing gene therapy solutions for these conditions, with research and development conducted in the U.S. geographic area.
- Headquarters Philadelphia, United States
- Employees 60
- Founders Stephen Squinto
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website passagebio.com
- Social LinkedIn
- Legal Name Passage Bio, Inc.
- Net Profit-$45.52 M (USD)29.71as on Dec 31, 2025
- EBITDA-$42.42 M (USD)31.67as on Dec 31, 2025
- Total Equity Funding$225.5M (USD)
in 3 rounds
- Latest Funding Round$50M (USD), Post-IPO
Sep 2021
- InvestorsNew Leaf Venture Partners
& 10 more
- Employee Count60
Funding Insights of Passage Bio
Passage Bio has successfully raised a total of $225.5M across 3 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in September 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $225.5M
- Total Rounds 3
- Last Round Post-IPO — $50M
- First Round $115.5M
(Feb 2019)
- Investors Count 11
All 3 funding rounds of Passage Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2021 | $50M | Post-IPO | – | – | |
| Sep 2019 | $110M | Series B | – | Access Biotechnology | |
| Feb 2019 | $115.5M | Series A | – | Orbimed |
11 investors in total: 11 institutional.
Investors in Passage Bio
Passage Bio has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include New Leaf Venture Partners, Orbimed and Frazier Healthcare Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital firm managing investments in biotechnology and pharmaceuticals since 1999. | versantventures.com | |||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States | |
Healthcare sector private equity investments are managed by the firm. | 1991 | frazierhealthcare.com | Seattle, United States | |
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Stage-agnostic investments in US life sciences are managed. | 2005 | nlvpartners.com | New York, United States | |
Venture capital and private equity firm | vivocapital.com | Palo Alto, United States | ||
Private equity fund focused on the biotechnology sector | logoscapital.com | San Francisco, United States | ||
| lillyasiaventures.com | ||||
Investment firm managing mid and large cap U.S. equities portfolios via fundamental research. | 1995 | highlinecap.com | New York, United States | |
Manages hedge funds with long/short equity and real estate strategies for investors. | 2004 | spherafund.com | Tel Aviv, Israel |
Investor details for Passage Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Passage Bio
30 people are tracked at Passage Bio (20 in leadership, 6 in board & advisors, 4 in team); the tracked headcount is 60.
| Name | Role | Group |
|---|---|---|
Stephen Squinto | Co-Founder | Leadership |
William Chou | CEO | Leadership |
Jasmine Li | Executive Director Of Analytical Development & Quality Control | Leadership |
Paulette Triglia | Executive Director, Clinical Operations | Leadership |
Jiwen Zhang | VP, Regulatory Affairs | Leadership |
Sue Browne | VP, Biology | Leadership |
Tiffini Voss | VP, Clinical Development | Leadership |
Stuart Henderson | VP, Corporate Development & Investor Relations | Leadership |
James M. Wilson | Chief Scientific Advisor | Leadership |
Samiah Al-Zaidy | VP, Clinical Development | Leadership |
Kathleen Borthwick | VP, Financial Planning & Analysis | Leadership |
Susan Browne | Senior Vice President, Research & Development | Leadership |
Glen Kerker II | Director, Regulatory Operations | Leadership |
Steve Krausert | Vice President, Supply Chain & Planning | Leadership |
Dave Bottari | Head Of Quality Assurance - Executive Director | Leadership |
Sharath Vallabhajosyula | Associate Director, Biomarker Operations | Leadership |
Joshua Benton | Director Of Manufacturing Technical Operations | Leadership |
Pamela H. | Vice President Clinical Operations | Leadership |
Karl Whitney | Senior Vice President, Global Regulatory Affairs | Leadership |
Chelsea Difebbo Ortiz | Executive Director, Patient Advocacy | Leadership |
10 more people are available in the full profile.
Complete people profiles for Passage Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Passage Bio
Passage Bio is a publicly listed company on the NASDAQ with ticker symbol PASG in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Feb 2020
- Listed onNASDAQ: PASG
- Listed entityPassage Bio, Inc.
- Exchange sectorHealth technology
- ISINUS7027122099
- Share price$3.64 (-20% on the day) · 2026-10-13
- Market capitalisation$11.7M
- EPS (diluted, trailing year)$-11.31
- Volume (last session)14,219
Financials of Passage Bio
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$45.5M | -$42.4M | |
| 2024 | -$64.8M | -$62.1M | |
| 2023 | -$102.1M | -$96.4M | |
| 2022 | -$136.1M | -$125.6M | |
| 2021 | -$185.4M | -$176.2M |
Detailed financial statements for Passage Bio
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Passage Bio
4 dated milestones of Passage Bio across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Passage Bio is founded.
- Funding First funding round of $115.5M.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $50.0M.
Competitors of Passage Bio
Passage Bio has 3 listed competitors in our database, 3 of them funded. They include BridgeBio, Spark Therapeutics and Alnylam.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. |
Detailed competitors of Passage Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Passage Bio
The website of Passage Bio (passagebio.com) receives about 6.9K visits a month and ranks #3,738,748 among all websites worldwide, #4,786 in Biotechnology and Pharmaceuticals.
- Monthly visits6.9K
▲ 41.3% vs previous month
- Unique visitors2K
per month
- Global rank#3,738,748
among all websites
- Category rank#4,786
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit1.9
- Average visit37 sec
- DevicesDesktop 32% · Mobile 68%
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Passage Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Passage Bio
Complete news archive for Passage Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Passage Bio
Passage Bio was founded in 2017 and raised its 1st funding round 2 years after it was founded.
Passage Bio is headquartered in Philadelphia, United States. It is registered at Philadelphia, Pennsylvania, United States.
William Chou is the CEO of Passage Bio, as recorded in our data.
Passage Bio is a funded company, having raised a total of $225.5M across 3 funding rounds to date. The company's 1st funding round was a Series A of $115.5M, raised on Feb 2019.
Passage Bio has 60 employees.
Passage Bio was founded in 2017 in Philadelphia, United States, within the biotechnology sector. AAV-delivered therapeutics are developed for rare monogenic central nervous system diseases. Lead programs are directed toward GM1 gangliosidosis, frontotemporal dementia, and Krabbe disease. Operations center on advancing gene therapy solutions for these conditions, with research and development conducted in the U.S. geographic area.
Passage Bio's top competitors include Spark Therapeutics, BridgeBio and Alnylam.
Yes, Passage Bio is publicly traded on NASDAQ under the ticker symbol PASG.
Passage Bio has 11 investors. Key investors include New Leaf Venture Partners, Orbimed, Frazier Healthcare Partners, Versant Ventures, and Lilly Asia Ventures.